Archive: Legal, Ethical and Policy Considerations in Adopting Pathogen Reduction Technology
258 views · Published 20 October 2015 · 57:59 · Indexed 12 November 2026
Channel: UW Video · 2015 · Education
Upon arrival of 2015, FDA surprised the transfusion medicine community by announcing its licensure of pathogen-reduced apheresis platelets and plasma. Pathogen reduction technology has been a "holy grail" of transfusion medicine because it can inactivate a broad spectrum of infectious agents, known and unknown. The technology is expensive, however, and the risk profile, while encouraging so far, is not fully defined. This talk will present a framework for risk-based decision making on the adoption of pathogen reduction, with an emphasis on legal and ethical considerations that impact policy formulation. James Barbeau, MD, JD, director, Clinical Pathology, Brown University 09/30/2015 https://uw.edu/video The University of Washington is committed to ensuring digital accessibility in our services, programs, and activities. If you encounter accessibility barriers using videos found on this channel, please contact UW Video at uwvideo [at] uw [dot] edu.
More from this channel
-
54:45
Archive: Usable Privacy and Security: Protecting People from Online Phishing Scams
-
58:27
Archive: Technology for Long-Term Care: Scaling Elder Care to the Next Billion
-
53:34
Archive: Closing the Innovation Gap
-
52:34
Archive: Hardness Amplification by Repetition
-
54:57
Archive: Network Coded Wireless Architecture
-
56:48
Archive: Computer Science Research for Global Development
-
58:16
Archive: Thinking Historically about Thinking Historically: Identity Politics to Ethical Action
-
27:18
Archive: Eastside Specialty Center: Coordination of Care